Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 6/17/2008 First Published: 8/6/2006


1.		Phase II Randomized Study of Imatinib Mesylate, Interferon alfa, and Sargramostim (GM-CSF) Versus Imatinib Mesylate and GM-K562 Cell Vaccine in Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Achieved a Complete Cytogenetic Response to Single-Agent Imatinib Mesylate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				JHOC-J05121 NCT00363649


2.		Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				06-196 NCT00442130


3.		Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				40 and over				Other				06-275 NCT00487305

Last Modified: 11/18/2008 First Published: 4/8/2008


4.		Phase I Study of Adjuvant Cyclophosphamide and Adjuvant Vaccine Therapy Comprising Allogeneic Colon Cancer Cells and K562/GM-CSF Cells in Patients With Resected Hepatic Metastases Secondary to Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				JHOC-J0745 J0745, JHOC-NA_00009345, NCT00656123


5.		Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				06-349 NCT00694330


6.		Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 to 70				NCI, Other				08-160 NCT00809250

Last Modified: 12/1/2008 First Published: 7/25/2006


7.		Study of GM-K562 Cell Vaccine in Patients With Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				JHOC-J05115 NCT00361296

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute